Evidence map›Paper›PMID 35108036›Full record

ArticleJCO precision oncology2022

Clinical and Molecular Characterization of

Benjamin Garmezy, Jinesh Gheeya, Heather Y Lin, Yuefan Huang, Taebeom Kim, Xianli Jiang, Kyaw Z Thein, Patrick G Pilié, Fadl Zeineddine, Wanlin Wang and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 4 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 4 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Guideline
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Advances in Cancer Immunotherapy for Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Benjamin GarmezyDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-2790-6235
Jinesh GheeyaThe University of Texas Health Science Center at Houston, Houston, TX.ORCID 0000-0002-5246-6262
Heather Y LinDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-1779-7007
Yuefan HuangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Taebeom KimDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-4970-3343
Xianli JiangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1697-8575
Kyaw Z TheinDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-1518-1097
Patrick G PiliéDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Fadl ZeineddineDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Wanlin WangDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.
Kenna R ShawKhalifa Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-6873-0793
Jordi RodonDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6467-3632
John Paul ShenDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-4588-2775
Ying YuanDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-3163-480X
Funda Meric-BernstamDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-6816-6072
Ken ChenDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-4013-5279
Timothy A YapDepartment of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX.
The University of Texas MD Anderson Cancer Center · USThe University of Texas Health Science Center at Houston · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M
Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic CancerP50CA221707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KOPETZ, SCOTT, MAITRA, ANIRBAN · 2019 to 2023
$11.0M
Informatics for Functional Integration of Heterogeneous Cancer Genome and Transcriptome Sequencing DataU01CA247760 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHEN, KEN · 2020 to 2022
$1.2M
High-Throughput Functional Genomics to Guide Precision Oncology in Gastrointestinal TumorsK22CA234406 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHEN, JOHN PAUL YING CHING · 2019 to 2021
$577k
NCATS NIH HHS UL1 TR000371NCI NIH HHS K22 CA234406NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA127001NCI NIH HHS P50 CA221707NCI NIH HHS U01 CA247760
6 · The paper itself

Abstract

purposeDNA polymerase epsilon is critical to DNA proofreading and replication. Mutations in

methodsWe conducted a retrospective analysis of next-generation sequencing data at MD Anderson Cancer Center to identify patient tumors with

resultsFour hundred fifty-eight patient tumors with

conclusionPathogenic

Indexed as

Immune Checkpoint InhibitorsNeoplasmsBiomarkersDNA Polymerase IIHumansMutationPoly-ADP-Ribose Binding ProteinsRetrospective StudiesBiomarkersDNA Polymerase IIImmune Checkpoint InhibitorsPOLE protein, humanPoly-ADP-Ribose Binding Proteins

Identifiers

PMID35108036
PMCPMC8820927
OpenAlexW4210316372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.